GoodRx Holdings, Inc. (NASDAQ:GDRX) Short Interest Update

Key Points

• GoodRx Holdings experienced a notable increase in short interest for August, rising by 24.4% to 6,680,000 shares, accounting for 8.2% of its total shares sold short.
• The company's stock opened at $4.10, reflecting a decline of 3.1%, with a twelve-month trading range between $3.31 and $7.61.
• GoodRx's quarterly earnings report indicated a missed estimate with earnings per share of $0.09 against the consensus of $0.10, alongside a revenue increase of 1.2% year-over-year.

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) saw a large growth in short interest in the month of August. As of August 31st, there was short interest totaling 6,680,000 shares, a growth of 24.4% from the August 15th total of 5,370,000 shares. Based on an average daily trading volume, of 2,970,000 shares, the short-interest ratio is currently 2.2 days. Currently, 8.2% of the company's shares are sold short. Currently, 8.2% of the company's shares are sold short. Based on an average daily trading volume, of 2,970,000 shares, the short-interest ratio is currently 2.2 days.

Insider Transactions at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 16,016 shares of the firm's stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $4.05, for a total value of $64,864.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 4.17% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Raymond James Financial Inc. boosted its holdings in GoodRx by 54.6% in the first quarter. Raymond James Financial Inc. now owns 830,950 shares of the company's stock worth $3,664,000 after purchasing an additional 293,420 shares during the period. Northwestern Mutual Wealth Management Co. boosted its holdings in GoodRx by 20,956.5% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 14,529 shares of the company's stock worth $64,000 after buying an additional 14,460 shares in the last quarter. Algert Global LLC purchased a new position in GoodRx in the 1st quarter worth about $1,224,000. Northern Trust Corp raised its holdings in shares of GoodRx by 13.5% during the fourth quarter. Northern Trust Corp now owns 421,810 shares of the company's stock valued at $1,961,000 after acquiring an additional 50,256 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of GoodRx in the first quarter worth $315,000. Hedge funds and other institutional investors own 63.77% of the company's stock.

Wall Street Analyst Weigh In

GDRX has been the subject of a number of recent research reports. Raymond James Financial downgraded GoodRx from a "strong-buy" rating to an "outperform" rating in a report on Friday, August 8th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and issued a $6.00 price target on shares of GoodRx in a research note on Monday, August 11th. Five investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $5.80.

GoodRx Trading Down 0.6%

Shares of NASDAQ GDRX traded down $0.03 during mid-day trading on Monday, reaching $4.11. 873,552 shares of the company's stock were exchanged, compared to its average volume of 2,028,784. GoodRx has a 52-week low of $3.31 and a 52-week high of $7.20. The company's 50-day moving average is $4.37 and its 200-day moving average is $4.41. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of 41.05, a PEG ratio of 1.80 and a beta of 1.23. The company has a debt-to-equity ratio of 0.75, a quick ratio of 4.21 and a current ratio of 4.21.

GoodRx (NASDAQ:GDRX - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.01). GoodRx had a net margin of 4.33% and a return on equity of 8.86%. The company had revenue of $203.07 million for the quarter, compared to analysts' expectations of $205.72 million. During the same period in the prior year, the company earned $0.08 earnings per share. The firm's revenue was up 1.2% on a year-over-year basis. Analysts expect that GoodRx will post 0.13 EPS for the current fiscal year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.